Want to see IN:JAGSNPHARM full AI Analyst Report?
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) Stock Forecast & Price Target
JAGSNPHARM Analyst Ratings
There are no analyst ratings in the last 3 months.
JAGSNPHARM Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| PerPlexity - SonarReasoningPro | TipRanks - PerPlexity | INR 261→INR 263 | buy | 21.25%Upside | Reiterated | 08/19/26 | ||
| OpenAI - Gpt-5.6Sol | TipRanks - OpenAI | INR 266→INR 272 | buy | 25.40%Upside | Reiterated | 08/06/26 | ||
| DeepSeek - V4Pro | TipRanks - DeepSeek | INR 266→INR 275 | buy | 26.79%Upside | Reiterated | 08/06/26 | ||
| Anthropic General IN | TipRanks - Anthropic | INR 256→INR 258 | hold | 18.95%Upside | Reiterated | 08/06/26 | ||
| xAI - Grok-4.3 | TipRanks - xAI | INR 265→INR 270 | buy | 24.48%Upside | Reiterated | 08/06/26 | ||
| Google General IN | TipRanks - Google | INR 269→INR 273 | buy | 25.86%Upside | Reiterated | 08/06/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| PerPlexity - SonarReasoningPro | 08/19/26 | INR 261→INR 263 | buy | 21.25%Upside | Reiterated | TipRanks - PerPlexity | ||
| OpenAI - Gpt-5.6Sol | 08/06/26 | INR 266→INR 272 | buy | 25.40%Upside | Reiterated | TipRanks - OpenAI | ||
| DeepSeek - V4Pro | 08/06/26 | INR 266→INR 275 | buy | 26.79%Upside | Reiterated | TipRanks - DeepSeek | ||
| Anthropic General IN | 08/06/26 | INR 256→INR 258 | hold | 18.95%Upside | Reiterated | TipRanks - Anthropic | ||
| xAI - Grok-4.3 | 08/06/26 | INR 265→INR 270 | buy | 24.48%Upside | Reiterated | TipRanks - xAI | ||
| Google General IN | 08/06/26 | INR 269→INR 273 | buy | 25.86%Upside | Reiterated | TipRanks - Google |
Best Analysts Covering Jagsonpal Pharmaceuticals Ltd.
Copying OpenAI General IN's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -9.40% per trade.
Copying OpenAI General IN's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.40% per trade.
Copying OpenAI General IN's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -9.40% per trade.
JAGSNPHARM Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 0 |
In the current month, JAGSNPHARM has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. JAGSNPHARM average Analyst price target in the past 3 months is ―.
JAGSNPHARM Financial Forecast
JAGSNPHARM Earnings Forecast
Next quarter’s earnings estimate for JAGSNPHARM is INR 1.86 with a range of ― to ―. The previous quarter’s EPS was INR 1.86. JAGSNPHARM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year JAGSNPHARM has Performed in-line its overall industry.
JAGSNPHARM Sales Forecast
Next quarter’s sales forecast for JAGSNPHARM is INR 963.71M with a range of ― to ―. The previous quarter’s sales results were INR 963.71M. JAGSNPHARM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year JAGSNPHARM has Performed in-line its overall industry.